4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

By F. Cardoso, E. Senkus, A. Costa, E. Papadopoulos, M. Aapro, F. André, N. Harbeck, B. Aguilar Lopez, C. Barrios, J. Bergh and 32 more. Annals of Oncology, 2018

1,021 citations recorded by the source corpus.

F. Cardoso*, E. Senkus, A. Costa, E. Papadopoulos, M. Aapro, F. André, N. Harbeck, B. Aguilar Lopez, C. H. Barrios, J. Bergh, L. Biganzoli, C. B. Boers-Doets, M. J. Cardoso, L. A. Carey, J. Cortés, G. Curigliano, V. Diéras, N. S. El Saghir, A. Eniu, L. Fallowfield, P. A. Francis, K. Gelmon, S. R. D. Johnston, B. Kaufman, S. Koppikar, I. E. Krop, M. Mayer, G. Nakigudde, B. V. Offersen, S. Ohno, O. Pagani, S. Paluch-Shimon, F. Penault-Llorca, A. Prat, H. S. Rugo, G. W. Sledge, D. Spence, C. Thomssen, D. A. Vorobiof, B. Xu, L. Norton & E. P. Winer

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0a01bd97e7fbbc06d65f0472c551384e61adff47

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Masakazu Toi
2. S. Tolaney

Citations in the corpus

• Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) (2020, background): “Early recurrence within the first 2 years of adjuvant ET in HR1 breast cancer is known to represent primary endocrine resistance.(18) More than 75% of the early recurrences seen TABLE 1.”